Navigating Colchicine Toxicity: Essential Management for a Timeless Therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing concepts and expert guidance without original human data or systematic review methodology
PubMed 42618164 · doi:10.1016/j.jen.2026.03.003
What was done
This narrative review synthesized current literature regarding colchicine pharmacology, mechanisms of toxicity, risk factors, clinical presentation, diagnostic considerations, and management strategies, with an emphasis on emergency nursing practice.
What was found
The abstract reports no empirical numbers or quantitative data. It notes that colchicine toxicity typically begins with gastrointestinal symptoms and can progress to multiorgan dysfunction, bone marrow suppression, hepatic and renal failure, and cardiovascular collapse, or chronic neuromyopathy and cytopenia. With no specific antidote available, management relies on supportive measures (fluid/electrolyte repletion, decontamination, vasopressors, extracorporeal membrane oxygenation) and adjunctive therapies (intravenous lipid emulsion, N-acetylcysteine). High-risk groups include older adults, pediatric accidental ingestions, individuals with organ dysfunction, and those taking interacting medications (macrolides, azole antifungals, statins).
Why it matters
With expanding indications for colchicine into pericarditis and cardiovascular prevention, clinicians and emergency staff must recognize severe toxicity risks, critical drug interactions, and supportive care pathways despite the lack of a targeted antidote.
Limits
The paper is a narrative review with no primary empirical data, sample size, or systematic synthesis methodology reported in the abstract. No quantitative effect estimates or comparative management outcomes are provided.
Cited by
- supports Colchicine was utilized approximately 3,000 years ago in Egypt for reducing gout.